Mimosa pudica Linn. Root Extract-Mediated Synthesis of Zinc Oxide Nanoparticles: a Study of Glucose Uptake Efficiency on 3T3-L1 Adipocytes

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Chandrasekar Palanichamy, Pavadai Parasuraman, Panneerselvam Theivendren, Murugesan Sankaranarayanan, Madasamy Sundar, Selvaraj Kunjiappan
{"title":"Mimosa pudica Linn. Root Extract-Mediated Synthesis of Zinc Oxide Nanoparticles: a Study of Glucose Uptake Efficiency on 3T3-L1 Adipocytes","authors":"Chandrasekar Palanichamy,&nbsp;Pavadai Parasuraman,&nbsp;Panneerselvam Theivendren,&nbsp;Murugesan Sankaranarayanan,&nbsp;Madasamy Sundar,&nbsp;Selvaraj Kunjiappan","doi":"10.1007/s12247-025-10064-x","DOIUrl":null,"url":null,"abstract":"<div>\n \n <span>AbstractSection</span>\n Purpose\n <p><i>Mimosa pudica</i> is a medicinal plant conventionally used to cure various ailments, including diabetes and is a model for synthesizing new drug derivatives. This work evaluates the glucose utilization potential of Zinc oxide nanoparticles (ZnONPs) derived from the ethanol root extract of <i>M. pudica</i> in 3T3-L1 adipocyte cells.</p>\n \n <span>AbstractSection</span>\n Methods\n <p>Molecular modeling tools were used to predict the potential antidiabetic compounds from <i>M. pudica</i>. ZnONPs were biosynthesized using <i>M. pudica</i> extract, and their physicochemical properties were characterized using UV-visible, FTIR, XRD, DLS, XPS, and FESEM techniques. The in vitro cellular viability of synthesized ZnONPs and glucose utilization efficiency were examined in 3T3-L1 adipocytes.</p>\n \n <span>AbstractSection</span>\n Results\n <p>Using GC-MS and LC-MS analyses, 27 novel bioactive compounds were identified from <i>M. pudica</i> root extract. For the efficient glucose utilization in 3T3-L1 adipocytes, Dipeptidyl-peptidase 4 (DPP-4) inhibition plays a pivotal role, as three of the top binding-scored molecules from <i>M. pudica</i> were identified via molecular docking and dynamics simulation studies. 500 µg of ZnONPs exhibited 73.47 ± 1.59% cellular viability. Further, the in vitro glucose utilization efficiency of ZnONPs was evidenced in 3T3-L1 adipocytes, which displayed concentration-dependent glucose utilization. The effect of ZnONPs (30 µg) on glucose uptake was higher than that of 10 µg of metformin. Bioactive compounds from <i>M. pudica</i> extract might inactivate the DPP-4 enzyme activity and improve insulin release from the pancreas, lowering blood glucose levels via GLUT4 activation.</p>\n \n <span>AbstractSection</span>\n Conclusion\n <p>The findings imply that <i>M. pudica</i>-mediated synthesized ZnONPs might be a plant-based novel oral nanoformulation for managing diabetes mellitus (DM).</p>\n \n <span>AbstractSection</span>\n Graphical Abstract\n <div><figure><div><div><picture><source><img></source></picture></div></div></figure></div>\n \n </div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10064-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

AbstractSection Purpose

Mimosa pudica is a medicinal plant conventionally used to cure various ailments, including diabetes and is a model for synthesizing new drug derivatives. This work evaluates the glucose utilization potential of Zinc oxide nanoparticles (ZnONPs) derived from the ethanol root extract of M. pudica in 3T3-L1 adipocyte cells.

AbstractSection Methods

Molecular modeling tools were used to predict the potential antidiabetic compounds from M. pudica. ZnONPs were biosynthesized using M. pudica extract, and their physicochemical properties were characterized using UV-visible, FTIR, XRD, DLS, XPS, and FESEM techniques. The in vitro cellular viability of synthesized ZnONPs and glucose utilization efficiency were examined in 3T3-L1 adipocytes.

AbstractSection Results

Using GC-MS and LC-MS analyses, 27 novel bioactive compounds were identified from M. pudica root extract. For the efficient glucose utilization in 3T3-L1 adipocytes, Dipeptidyl-peptidase 4 (DPP-4) inhibition plays a pivotal role, as three of the top binding-scored molecules from M. pudica were identified via molecular docking and dynamics simulation studies. 500 µg of ZnONPs exhibited 73.47 ± 1.59% cellular viability. Further, the in vitro glucose utilization efficiency of ZnONPs was evidenced in 3T3-L1 adipocytes, which displayed concentration-dependent glucose utilization. The effect of ZnONPs (30 µg) on glucose uptake was higher than that of 10 µg of metformin. Bioactive compounds from M. pudica extract might inactivate the DPP-4 enzyme activity and improve insulin release from the pancreas, lowering blood glucose levels via GLUT4 activation.

AbstractSection Conclusion

The findings imply that M. pudica-mediated synthesized ZnONPs might be a plant-based novel oral nanoformulation for managing diabetes mellitus (DM).

AbstractSection Graphical Abstract
含羞草。根提取物介导的氧化锌纳米颗粒合成:3T3-L1脂肪细胞葡萄糖摄取效率的研究
【摘要】目的含羞草是治疗糖尿病等多种疾病的常用药用植物,是合成新型药物衍生物的典范。本研究评估了从臭毛霉乙醇根提取物中提取的氧化锌纳米颗粒(ZnONPs)在3T3-L1脂肪细胞中的葡萄糖利用潜力。【摘要】【章节】方法采用分子模拟方法预测霉属植物中潜在的抗糖尿病化合物。以牡丹提取物为原料合成ZnONPs,并利用uv -可见、FTIR、XRD、DLS、XPS和FESEM等技术对其理化性质进行了表征。在3T3-L1脂肪细胞中检测合成的ZnONPs体外细胞活力和葡萄糖利用效率。【摘要】【章节】结果通过GC-MS和LC-MS分析,鉴定出27个新的生物活性化合物。对于3T3-L1脂肪细胞的有效葡萄糖利用,二肽基肽酶4 (DPP-4)抑制起着关键作用,通过分子对接和动力学模拟研究鉴定了三种结合得分最高的pudica分子。500µg ZnONPs的细胞存活率为73.47±1.59%。此外,ZnONPs的体外葡萄糖利用效率在3T3-L1脂肪细胞中得到证实,其葡萄糖利用表现出浓度依赖性。ZnONPs(30µg)对葡萄糖摄取的影响高于二甲双胍(10µg)。阴毛菌提取物中的生物活性化合物可能会使DPP-4酶活性失活,改善胰腺胰岛素释放,通过激活GLUT4降低血糖水平。结论本研究结果提示,紫荆分枝杆菌介导合成的ZnONPs可能是一种以植物为基础的新型口服纳米制剂,用于治疗糖尿病。摘要节图形摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信